生物模擬市場機會、成長動力、產業趨勢分析與 2025 - 2034 年預測

2024 年全球生物模擬市場規模達到 42 億資料，預計 2025 年至 2034 年期間複合年成長率將達到 17.7%。這項創新技術提供了對不同條件下生物行為的無與倫比的洞察，支持藥物發現、臨床試驗最佳化和個人化醫療開發等關鍵領域。

透過使研究人員能夠以極高的精度模擬複雜的生物過程，生物模擬正在改變治療方法的開發、評估和最佳化方式。它在降低開發成本、減輕風險和提高整體效率方面的作用使其成為現代醫療保健創新的基石。精準醫療的需求不斷成長以及人工智慧和機器學習的日益應用進一步放大了生物模擬在醫療保健和製藥行業的重要性。

市場根據產品（包括軟體和服務）進行細分。 2024 年，軟體領域將佔據 62.4% 的佔有率，這得益於其利用機器學習和先進演算法模擬複雜生物系統的能力。生物模擬軟體主要分為兩大類：整合軟體套件/平台和獨立模組。該技術透過提高藥物功效和安全性的預測能力，增強了研究人員的能力，使他們能夠在開發週期的早期就發現有前景的候選藥物。這種早期識別加速了開發過程並顯著降低了相關成本，增強了生物模擬在簡化研發操作方面的價值。

生物模擬的應用涵蓋多個領域，其中藥物發現將在 2024 年引領市場，佔據 42.5% 的佔有率。預計藥物研發領域將大幅成長，到 2034 年將達到 91 億美元。研究人員可以模擬生物過程、改進分子設計並精確驗證目標，從而提高治療效果並縮短新療法的上市時間。對候選藥物和生物系統之間複雜相互作用進行建模的能力將改變遊戲規則，推動生物模擬市場向醫療保健領域的變革性進步邁進。

美國將繼續保持生物模擬創新領域的全球領先地位，預計到 2034 年其市場規模將達到 76 億美元。精準醫療的廣泛應用嚴重依賴生物模擬來開發客製化療法，這進一步推動了市場的成長。基於基因圖譜的個人化治療確保了對先進生物模擬工具的持續需求，加強了美國在臨床和研究應用領域的開創性進步中的作用。

目錄

第 1 章：方法論與範圍

第 2 章：執行摘要

第 3 章：產業洞察

• 產業生態系統分析
• 產業衝擊力
  • 成長動力
    • 慢性病盛行率上升
    • 計算建模的技術進步
    • 個人化醫療需求不斷成長
    • 增加人工智慧和機器學習的使用
  • 產業陷阱與挑戰
    • 生物模擬軟體和服務成本高昂
    • 缺乏熟練的專業人員
• 成長潛力分析
• 監管格局
• 技術格局
• 未來市場趨勢
• 波特的分析
• PESTEL 分析

第4章：競爭格局

• 介紹
• 公司市佔率分析
• 公司矩陣分析
• 主要市場參與者的競爭分析
• 競爭定位矩陣
• 策略儀表板

第5章：市場估計與預測：按供應量，2021 – 2034 年

• 主要趨勢
• 軟體
  • 整合軟體套件/平台
    • 分子建模和模擬軟體
    • 臨床試驗設計軟體
    • PK/PD 建模和模擬軟體
    • Pbpk建模與模擬軟體
    • 毒性預測軟體
    • 其他整合軟體套件/平台
  • 獨立模組
• 服務

第 6 章：市場估計與預測：按應用，2021 年至 2034 年

• 主要趨勢
• 藥物研發
• 藥物開發
• 疾病模型
• 其他應用

第 7 章：市場估計與預測：按治療領域，2021 年至 2034 年

• 主要趨勢
• 腫瘤學
• 心血管疾病
• 神經系統疾病
• 傳染病
• 其他治療領域

第 8 章：市場估計與預測：按交付模式，2021 年至 2034 年

• 主要趨勢
• 訂閱模式
• 所有權模式
  • 基於許可的模式
  • 按使用付費模式
• 基於服務的模型

第 9 章：市場估計與預測：按部署模型，2021 年至 2034 年

• 主要趨勢
• 本地模型
• 基於雲端的模型

第 10 章：市場估計與預測：依最終用途，2021 年至 2034 年

• 主要趨勢
• 製藥和生物技術公司
• 合約研究組織 (CRO)
• 學術研究機構

第 11 章：市場估計與預測：按地區，2021 年至 2034 年

• 主要趨勢
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 英國
  • 法國
  • 西班牙
  • 義大利
  • 荷蘭
• 亞太地區
  • 中國
  • 日本
  • 印度
  • 澳洲
  • 韓國
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中東和非洲
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

第 12 章：公司簡介

• Allucent
• Advanced Chemistry Development
• Certara, USA
• Cellworks
• Chemical Computing Group
• Dassault Systèmes
• Genedata
• In Silico Biosciences
• Immunetrics
• OpenEye
• Physiomics
• Simulations Plus
• Schrödinger
• Thermo Fisher Scientific
• VeriSIM Life

The Global Biosimulation Market reached USD 4.2 billion in 2024 and is projected to grow at an impressive CAGR of 17.7% between 2025 and 2034. Biosimulation, a cutting-edge approach in computational biology, leverages advanced mathematical models, sophisticated algorithms, and experimental data to replicate biological systems, processes, and interactions. This innovative technology delivers unparalleled insights into biological behavior under diverse conditions, supporting critical sectors such as drug discovery, clinical trial optimization, and personalized medicine development.

By enabling researchers to simulate complex biological processes with exceptional accuracy, biosimulation is transforming how therapies are developed, assessed, and optimized. Its role in reducing development costs, mitigating risks, and enhancing overall efficiency makes it a cornerstone of modern healthcare innovation. The growing demand for precision medicine and the increasing adoption of artificial intelligence and machine learning further amplify the significance of biosimulation in the healthcare and pharmaceutical industries.

The market is segmented based on offerings, including software and services. In 2024, the software segment dominated with a 62.4% share, driven by its ability to leverage machine learning and advanced algorithms for simulating intricate biological systems. Biosimulation software is available in two primary categories: integrated software suites/platforms and standalone modules. This technology empowers researchers by improving the prediction of drug efficacy and safety, enabling the identification of promising drug candidates earlier in the development cycle. This early identification accelerates the development process and significantly reduces associated costs, reinforcing the value of biosimulation in streamlining research and development operations.

Applications of biosimulation span multiple domains, with drug discovery leading the market in 2024, accounting for a 42.5% share. The drug discovery segment is anticipated to grow substantially, reaching USD 9.1 billion by 2034. Biosimulation enables the use of computational models to predict the behavior of potential drugs, minimizing the likelihood of costly late-stage failures. Researchers can simulate biological processes, refine molecular designs, and validate targets with precision, enhancing therapeutic efficacy and reducing time-to-market for new treatments. The ability to model complex interactions between drug candidates and biological systems is a game-changer, propelling the biosimulation market toward transformative advancements in healthcare.

The United States is set to remain a global leader in biosimulation innovation, with its market projected to reach USD 7.6 billion by 2034. The country's robust ecosystem, featuring premier research institutions and universities, underpins advancements in computational biology and biosimulation. The widespread adoption of precision medicine, which relies heavily on biosimulation to develop tailored therapies, further fuels market growth. The focus on personalized treatments based on genetic profiles ensures sustained demand for advanced biosimulation tools, strengthening the role of the U.S. in pioneering advancements across clinical and research applications.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° Synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising prevalence of chronic diseases
    • 3.2.1.2 Technological advancements in computational modeling
    • 3.2.1.3 Rising demand for personalized medicine
    • 3.2.1.4 Increasing use of AI and machine Learning
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High costs of biosimulation software and services
    • 3.2.2.2 Lack of skilled professionals
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Technological landscape
• 3.6 Future market trends
• 3.7 Porter's analysis
• 3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Offering, 2021 – 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Software
  • 5.2.1 Integrated software suites/platform
    • 5.2.1.1 Molecular modeling and simulation software
    • 5.2.1.2 Clinical trial design software
    • 5.2.1.3 PK/PD modeling and simulation software
    • 5.2.1.4 Pbpk modeling and simulation software
    • 5.2.1.5 Toxicity prediction software
    • 5.2.1.6 Other integrated software suites/platforms
  • 5.2.2 Standalone modules
• 5.3 Service

Chapter 6 Market Estimates and Forecast, By Application, 2021 – 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Drug discovery
• 6.3 Drug development
• 6.4 Disease modeling
• 6.5 Other applications

Chapter 7 Market Estimates and Forecast, By Therapeutic Area, 2021 – 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Oncology
• 7.3 Cardiovascular disease
• 7.4 Neurological disorder
• 7.5 Infectious diseases
• 7.6 Other therapeutic areas

Chapter 8 Market Estimates and Forecast, By Delivery Model, 2021 – 2034 ($ Mn)

• 8.1 Key trends
• 8.2 Subscription models
• 8.3 Ownership models
  • 8.3.1 License-based model
  • 8.3.2 Pay per use model
• 8.4 Service based models

Chapter 9 Market Estimates and Forecast, By Deployment Model, 2021 – 2034 ($ Mn)

• 9.1 Key trends
• 9.2 On premises model
• 9.3 Cloud based model

Chapter 10 Market Estimates and Forecast, By End Use, 2021 – 2034 ($ Mn)

• 10.1 Key trends
• 10.2 Pharmaceutical and biotechnology companies
• 10.3 Contract research organizations (CROs)
• 10.4 Academic research institutions

Chapter 11 Market Estimates and Forecast, By Region, 2021 – 2034 ($ Mn)

• 11.1 Key trends
• 11.2 North America
  • 11.2.1 U.S.
  • 11.2.2 Canada
• 11.3 Europe
  • 11.3.1 Germany
  • 11.3.2 UK
  • 11.3.3 France
  • 11.3.4 Spain
  • 11.3.5 Italy
  • 11.3.6 Netherlands
• 11.4 Asia Pacific
  • 11.4.1 China
  • 11.4.2 Japan
  • 11.4.3 India
  • 11.4.4 Australia
  • 11.4.5 South Korea
• 11.5 Latin America
  • 11.5.1 Brazil
  • 11.5.2 Mexico
  • 11.5.3 Argentina
• 11.6 Middle East and Africa
  • 11.6.1 South Africa
  • 11.6.2 Saudi Arabia
  • 11.6.3 UAE

Chapter 12 Company Profiles

• 12.1 Allucent
• 12.2 Advanced Chemistry Development
• 12.3 Certara, USA
• 12.4 Cellworks
• 12.5 Chemical Computing Group
• 12.6 Dassault Systèmes
• 12.7 Genedata
• 12.8 In Silico Biosciences
• 12.9 Immunetrics
• 12.10 OpenEye
• 12.11 Physiomics
• 12.12 Simulations Plus
• 12.13 Schrödinger
• 12.14 Thermo Fisher Scientific
• 12.15 VeriSIM Life